SYK and B-cell non-Hodgkin lymphoma: Importantly, although survival of NKX2-3 transgenic B cells from younger animals was moderately impaired after incubation with Lyn and Syk inhibitors, this impairment was significantly greater in 18-month-old clonal B-cell lymphoma cells (IC50 within low nano-molar ranges; Fig. 4g).